Form 4: Vaxcyte Officer Dhaliwal Reports RSU Tax Withholding

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, reported the surrender of shares to cover tax obligations related to RSU vesting.

Summary

• Harpreet S. Dhaliwal, Chief Technical Operations Officer of Vaxcyte, Inc., reported transactions on September 2, 2025.
• A total of 1,538 shares of Common Stock were surrendered to Vaxcyte, Inc. to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The shares were surrendered at a price of $31.56 per share.
• Following these transactions, Dhaliwal beneficially owns 34,874 shares of Common Stock.
• The reported beneficial ownership includes 329 shares acquired under Vaxcyte's Employee Stock Purchase Plan on May 16, 2025.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to RSU vesting and tax obligations, which is a standard event and does not indicate significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The vesting of RSUs represents a realization of compensation for the executive.
• The acquisition of 329 shares under the Employee Stock Purchase Plan on May 16, 2025, indicates continued participation in the company's equity programs.

Negatives

• The surrender of 1,538 shares reduces the direct beneficial ownership of the executive in the company's common stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive positioning.

Related Party Transactions

• The surrender of shares to the issuer (Vaxcyte, Inc.) to cover tax withholding obligations upon RSU vesting is a common related-party transaction in the context of executive compensation.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine executive compensation event and does not reflect a discretionary sale of shares by the insider.

Key Dates

Recommendation

This Form 4 details a standard executive transaction involving the surrender of shares for tax withholding upon RSU vesting, along with a minor ESPP acquisition. Such routine filings typically do not provide new material information that would warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions rather than this specific insider filing.

Keywords

Vaxcyte, PCVX, Harpreet S. Dhaliwal, Form 4, Insider Transaction, RSU Vesting, Tax Withholding, Employee Stock Purchase Plan, Executive Compensation